Innovent Biologics, Inc. (FRA:6IB)
Germany · Delayed Price · Currency is EUR 9.75
+0.15 (1.56%)
At close: Feb 20, 2026
Innovent Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 11,423 | 9,422 | 6,206 | 4,556 | 4,270 | 3,844 |
Revenue | 11,423 | 9,422 | 6,206 | 4,556 | 4,270 | 3,844 |
Revenue Growth (YoY) | 53.18% | 51.82% | 36.21% | 6.71% | 11.08% | 266.94% |
Cost of Revenue | 2,671 | 2,412 | 1,807 | 1,382 | 1,224 | 771.82 |
Gross Profit | 8,752 | 7,010 | 4,399 | 3,175 | 3,045 | 3,072 |
Selling, General & Admin | 5,703 | 5,085 | 3,851 | 3,426 | 3,426 | 1,778 |
Research & Development | 2,120 | 2,202 | 2,112 | 2,871 | 2,323 | 1,851 |
Operating Expenses | 7,822 | 7,287 | 5,963 | 6,297 | 5,749 | 3,629 |
Operating Income | 929.3 | -276.57 | -1,564 | -3,123 | -2,703 | -557.19 |
Interest Expense | -90.89 | -67.65 | -98.62 | -101.7 | -62.46 | -68.35 |
Interest & Investment Income | 376.54 | 423.45 | 452.84 | 189.54 | 151.76 | 116.1 |
Earnings From Equity Investments | -64.57 | -41.01 | - | - | - | - |
Currency Exchange Gain (Loss) | 28.5 | 130.28 | 60.82 | 752.05 | -198.75 | -509.74 |
Other Non Operating Income (Expenses) | 46.13 | 76.13 | 90 | 107.32 | 46.78 | 130.69 |
EBT Excluding Unusual Items | 1,225 | 244.64 | -1,059 | -2,176 | -2,766 | -888.49 |
Gain (Loss) on Sale of Investments | 189.14 | 179.03 | 30.81 | 5.1 | 125.02 | 30.98 |
Gain (Loss) on Sale of Assets | -0.61 | -22.99 | -0.95 | 0.06 | -0.71 | -1.2 |
Asset Writedown | -202.45 | -479.3 | -115.36 | - | - | - |
Pretax Income | 1,211 | -78.62 | -1,144 | -2,170 | -2,642 | -858.71 |
Income Tax Expense | 78.77 | 16.01 | -116.5 | 8.8 | 87.04 | 139.71 |
Earnings From Continuing Operations | 1,132 | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 |
Net Income | 1,132 | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 |
Net Income to Common | 1,132 | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 |
Shares Outstanding (Basic) | 1,637 | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 |
Shares Outstanding (Diluted) | 1,663 | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 |
Shares Change (YoY) | 3.74% | 4.35% | 4.67% | 2.37% | 7.27% | 15.23% |
EPS (Basic) | 0.69 | -0.06 | -0.66 | -1.46 | -1.87 | -0.74 |
EPS (Diluted) | 0.67 | -0.06 | -0.66 | -1.46 | -1.88 | -0.74 |
Free Cash Flow | 1,448 | 321.36 | -971.58 | -2,816 | -3,090 | -796.71 |
Free Cash Flow Per Share | 0.87 | 0.20 | -0.62 | -1.89 | -2.12 | -0.59 |
Gross Margin | 76.62% | 74.40% | 70.89% | 69.67% | 71.32% | 79.92% |
Operating Margin | 8.14% | -2.94% | -25.20% | -68.54% | -63.31% | -14.50% |
Profit Margin | 9.91% | -1.00% | -16.56% | -47.83% | -63.91% | -25.97% |
Free Cash Flow Margin | 12.67% | 3.41% | -15.65% | -61.80% | -72.38% | -20.73% |
EBITDA | 1,302 | 23.99 | -1,288 | -2,878 | -2,538 | -489.2 |
EBITDA Margin | 11.40% | 0.26% | -20.76% | -63.16% | -59.44% | -12.73% |
D&A For EBITDA | 373.13 | 300.56 | 275.6 | 245.09 | 165.4 | 67.98 |
EBIT | 929.3 | -276.57 | -1,564 | -3,123 | -2,703 | -557.19 |
EBIT Margin | 8.14% | -2.94% | -25.20% | -68.54% | -63.31% | -14.50% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.